Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1996 Apr;19(2):135-9.
doi: 10.1007/BF02805227.

Granulocyte-colony stimulating factor produced by pancreatic carcinoma

Affiliations
Case Reports

Granulocyte-colony stimulating factor produced by pancreatic carcinoma

T Uematsu et al. Int J Pancreatol. 1996 Apr.

Abstract

Conclusion: A rare case of granulocyte-colony stimulating factor (G-CSF) produced by carcinoma of the pancreas has been reported.

Background: This is the first case showing high G-CSF concentration in the aspirated tumor fluid (mucin) at its early stage without leukocytosis.

Methods: The tumor, detected incidentally in a 64-yr-old male, was removed by a distal pancreatectomy. The mass was 7.0 x 6.5 x 4.5 cm, and was histologically diagnosed as cystadenocarcinoma with prominent sarcomatous transformation. It was classified as anaplastic carcinoma.

Results: After 4 wk of resection, progressive leukocytosis was observed. Seven weeks after the operations, the peripheral leukocyte count increased to 126,000/mL. After 8 wk of resection, the patient died of recurrence. The serum G-CSF concentration was elevated after recurrence. The preserved mucin contained in the cystic components of the resected specimen had a G-CSF concentration higher than 2400 pg/mL. G-CSF is a known cytokine and an etiologic agent in paraneoplastic syndromes. An early diagnosis can, therefore, be made prior to the manifestation of clinical symptoms by the evaluation of the aspirated tumor fluid. This can lead to the prevention of the paraneoplastic syndrome with inhibitory cytokines in future.

PubMed Disclaimer

References

    1. J Immunol Methods. 1989 Mar 31;118(2):187-92 - PubMed
    1. Melanoma Res. 1992 Sep;2(3):181-9 - PubMed
    1. J Biol Chem. 1979 Jul 25;254(14):6226-8 - PubMed
    1. Aust J Exp Biol Med Sci. 1966 Jun;44(3):287-99 - PubMed
    1. Cancer. 1951 Sep;4(5):930-5 - PubMed

Publication types

Substances

LinkOut - more resources